CALGB 80405 PDF
ASCO, ITT, KRAS-WT primary OS results: CALGB failed to meet its primary endpoint of OS Cetuximab is not superior to Avastin in 1L KRAS-WT. CALGB/SWOG Phase III trial of FOLFIRI or mFOLFOX6 with bevacizumab or cetuximab for patients with expanded RAS analyses in. CALGB/SWOG Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab.
|Published (Last):||28 July 2014|
|PDF File Size:||12.68 Mb|
|ePub File Size:||2.70 Mb|
|Price:||Free* [*Free Regsitration Required]|
These results differ from 2 smaller but contemporary studies that asked a similar question.
Create a free personal account to make a comment, download free article PDFs, sign up for alerts and more. Data quality was reviewed and audited by the Alliance Statistics and Data Center and by the study chairperson following Alliance policies.
84005 Boundaries were truncated at 2. No Difference, but Not the Same. Create a free personal account to download free article PDFs, sign up for alerts, customize your interests, and more. The last date of follow-up was December 15, Toxic effects that were lower than grade 3 were distinct with acneiform rash predominating for cetuximab and hypertension predominating for bevacizumab.
New guidelines to evaluate response to treatment in solid tumors.
Meeting Library | Meeting Library
Accessed May 26, Main Outcomes and Measures: No significant interactions were observed for sex HR for interaction, 0. Key Points Those with left-sided tumors had longer median overall survival Secondary objectives included progression-free survival and overall response rate, site-reported confirmed or unconfirmed complete or partial response. Of patients, Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the optimal choice of the initial biologic therapy in previously untreated patients is unknown.
Eligible patients had pathology-documented untreated locally advanced or metastatic colorectal cancer, although measurable disease tumor that could be quantified was not require.
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. The last date of follow-up was December 15, Results are reported for 1 the primary 2-group comparison between cetuximab and bevacizumab; 2 the comparison of cetuximab vs bevacizumab in an expanded RAS subset described above; and 3 the chemotherapy subgroups. Among patients who received cetuximab, patients with left-sided tumors lived 36 months, whereas those with right-sided tumors lived The Kaplan-Meier method was used to estimate overall and progression-free survival.
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: Get free access to newly published articles.
Third, one element not included in the on-study information was primary cancer site eg, right vs left colon. Patients enrolled and consented to the companion study whose tumor was KRAS wt and who received single antibody treatment were included in the primary cohort.
Critical revision of the manuscript for important intellectual content: Secondary end points included response rate site-reported confirmed or unconfirmed complete or partial response by RECIST [Response 8045 Criteria in Solid Tumors] and progression-free survival measured from study entry until first documented progression or death.
Eli Lilly provided the cetuximab.
Within each treatment group, the hypothesis that the arterial thrombotic event rate was 0. This also contributed to the survival results.
The median progression-free survival was The primary outcome of progression-free survival was not statistically different between the panitumumab and bevacizumab treatment groups Sign in to access your subscriptions Sign in to your personal account. Purchase access Subscribe to JN Learning for one year.
However, there was a significant difference in overall survival between panitumumab and bevacizumab An additional secondary end point was day mortality assessed as the proportion of patients calyb due to any cause within 60 days of beginning protocol therapy. Toxicity and response criteria of the Eastern Calbg Oncology Group.
From November to September patients were randomized 1: It is also an important reminder, in this exciting era of precision medicine, that genomics is not the only source of insight into how cancers should be studied and treated.
The median overall survival was